Newsroom

Events & Presentations

April 2, 2017: Dr. Ryan J. Sullivan, Harvard Medical School / MGH, Boston, MA presented “Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma” at the AACR meeting in Washington, DC. [Presentation]

November 29 - December 2, 2016: Filip Janku presented a poster at the 28th EORTC-NCI-AACR Symposium, Munich, Germany. Abstract: Janku F, et al. Phase I clinical study of intratumoral injection of oncolytic Clostridium novyi-NT spores in patients with advanced cancers. European Journal of Cancer December 2016 Volume 69, Supplement 1, Page S94. [Abstract]

May 29 - June 2, 2015: Members of BioMed Valley Discoveries attended the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The following abstract was presented by Jeffrey Infante, MD, from Sarah Cannon Research Hospital: Infante JR, Janku F, Tolcher AW, Patel MR, Sullivan RJ, Flaherty K, Carvajal RD, Varghese AM, Lee Wong DJ, Sznol M, Sosman JA, Wang-Gillam A, Burris HA, Ribas A, Patel SP, Welsch DJ, Saha S. Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. 2015 American Society for Clinical Oncology Annual Meeting, Chicago, IL. Abstract nr 2506. [abstract] [related video]

April 18 – 22, 2015: Members of BioMed Valley Discoveries attended the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. The following abstract was presented by Dean Welsch, PhD: Germann U, Furey B, Roix J, Markland W, Hoover R, Aronov A, Hale M, Chen G, Martinez-Botella G, Alargova R, Fan B, Sorrell D, Meshaw K, Shapiro P, Wick MJ, Benes C, Garnett M, DeCrescenzo G, Namchuk M, Saha S, Welsch DJ. The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 4693. [abstract]

March 2 - 4, 2015: Filip Janku presented a poster at 13th International Congress on Targeted Anticancer Therapies (TAT), Paris, France. Abstract: Janku F, et al. Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer. Ann Oncol (2015) 26 (suppl 2):ii18. [Abstract]

January 31, 2015: Ravi Murthy gave an oral presentation at the 2015 Symposium on Clinical Interventional Oncology (CIO), Westin Diplomat, Hollywood, Florida. Abstract: Murthy R, et al. Phase 1 Trial of Image-guided Oncolysis by Clostridium Novyi-NT spore inoculation: Early technical insights. JVIR January 2015 Volume 26, Issue 1, Page 151. [Abstract]

Publications

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S, Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR, Dimitrov DS, St Croix B. Cancer Cell. 2017;31:501-515.e8. Abstract | Commentary

[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. Zhang XM, Zhang HH, McLeroth P, Berkowitz RD, Mont MA, Stabin MG, Siegel BA, Alavi A, Barnett TM, Gelb J, Petit C, Spaltro J, Cho SY, Pomper MG, Conklin JJ, Bettegowda C, Saha S. Nuclear Med Biol. 2016;43:273-279. Abstract

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA, Jr., Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S. Sci Transl Med. 2014;6:249ra111. Abstract

Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity. Roix JJ, Harrison SD, Rainbolt EA, Meshaw KR, McMurry AS, Cheung P, Saha S. PloS One. 2014;9:e101708. Abstract

Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent. Tung D, DeCrescenzo G, Welsch D, Cheung PH, Bettegowda C, Saha S. World J Microbiol Biotechnol. 2014;30:3003-3010. Abstract

MRI-monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model. Zheng L, Zhang Z, Khazaie K, Saha S, Lewandowski RJ, Zhang G, Larson AC. PloS One. 2014;9:e116204. Abstract

TNF-alpha blockade is ineffective in animal models of established polycystic kidney disease. Roix J, Saha S. BMC Nephrol. 2013;14:233. Abstract

Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. Tung D, Ciallella J, Cheung PH, Saha S. Pharmacology. 2013;91:29-34. Abstract

Possible therapeutic effect of trilostane in rodent models of inflammation and nociception. Tung D, Ciallella J, Hain H, Cheung PH, Saha S. Curr Ther Res Clin Exp. 2013;75:71-76. Abstract

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion. Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R. Diabetes Obes Metab. 2012;14:329-334. Abstract

Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis. Tung D, Cheung PH, Wilson J, Tudor G, Booth C, Saha S. Curr Ther Res Clin Exp. 2012;73:150-164. Abstract

Novel anti-inflammatory effects of repaglinide in rodent models of inflammation. Tung D, Cheung PH, Ciallella J, Saha S. Pharmacology. 2011;88:295-301. Abstract

Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Tung D, Cheung PH, Kaur P, Foreman O, Kavirayani A, Hain HS, Saha S. Pharmacology. 2011;88:100-113. Abstract

In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis. Tung D, Cheung PH, Tudor G, Booth C, Saha S. Curr Ther Res Clin Exp. 2011;72:262-272. Abstract

Contact our media relations team.